13 active not recruiting, 11 recruiting, 6 completed, 5 not yet recruiting. 45 Phase 2, 7 Phase 1.
Follow zimberelimab: new trials by email Literature Review of zimberelimab trials Research Report on zimberelimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Single-arm, Multicenter Clinical Study of Becotatug Vedotin Combined With Zimberelimab in the Treatment of Recurrent and Metastatic Cervical Cancer, Vulvar Cancer and Vaginal Cancer Becotatug Vedotin in combination with Zimberelimab - Uterine Cervical Neoplasms, Recurrent; Uterine Cervical Neoplasms, Metastatic; Vulvar Neoplasms; Vaginal Neoplasms | Phase 2 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 30 | 2026-06-11 | 2026-06-16 |
| Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC Zimberelimab (AB122), Domvanalimab (DOM), Sacituzumab Govitecan (SG) - Triple Negative Breast Cancer, PDL-1 Positive | Phase 2 | Withdrawn | MedSIR | 2026-04-01 | 2026-05-01 | |
| Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01) FOLFIRI + Zimberelimab + Domvanalimab, FOLFIRI (standard of care) - Carcinoma, Neuroendocrine | Phase 2 | Not yet recruiting | Hospices Civils de Lyon | 122 | 2026-04-01 | 2026-01-13 |
| Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC Casdatifan, Zimberelimab - Renal Cell Carcinoma, Kidney Cancer | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 32 | 2026-03-09 | 2026-03-20 |
| Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma Zimberelimab, Domvanalimab, FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel) - Adenocarcinoma Stomach, Adenocarcinoma Gastroesophageal Junction | Phase 2 | Withdrawn | Massachusetts General Hospital | 2026-02-01 | 2025-12-26 | |
| IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers DOMVANALIMAB + ZIMBERELIMAB, DOMVANALIMAB + ZIMBERELIMAB + FOLFOX-4 - Peritoneal Mesothelioma, Gestational Trophoblastic Tumor | Phase 2 | Active not recruiting | Hospices Civils de Lyon | 27 | 2025-10-01 | 2026-06-25 |
| Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01 Domvanalimab, Zimberelimab, Paclitaxel - Head and Neck Squamous Cell Carcinoma | Phase 2 | Active not recruiting | Gilead Sciences | 39 | 2025-02-18 | 2026-09-03 |
| PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer Sacituzumab govitecan, Zimberelimab, Domvanalimab - Urothelial Bladder Carcinoma | Phase 2 | Active not recruiting | Fundación para el Progreso de la Oncología en Cantabria | 70 | 2025-01-20 | 2026-10-07 |
| Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases Stereotactic Radiation, Zimberelimab, Sacituzumab govitecan - Breast Cancer, Triple Negative Breast Cancer | Phase 1 / Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 31 | 2024-12-19 | 2025-12-05 |
| Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer Sacituzumab Govitecan + Zimberelimab - Bladder Cancer, Bladder Urothelial Carcinoma | Phase 2 | Not yet recruiting | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 63 | 2024-12-02 | 2024-07-30 |
| Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma Stereotactic body radiotherapy (SBRT), Zimberelimab, Quemliclustat - Pancreatic Ductal Adenocarcinoma | Phase 2 | Recruiting | Gulam Manji | 60 | 2024-05-10 | 2026-02-27 |
| Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC) Gemcitabine, Cisplatin, Zimberelimab - Biliary Tract Carcinoma, Cholangiocarcinoma | Phase 2 | Active not recruiting | Nataliya Uboha | 33 | 2024-03-08 | 2026-08-17 |
| A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer Disitamab Vedotin, Zimberelimab - Cervical Cancer | Phase 2 | Recruiting | RemeGen Co., Ltd. | 116 | 2024-01-11 | 2024-02-28 |
| Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer Zimberelimab, Oxaliplatin, S-1 - Previously AG Chemotherapy Treated Pancreatic Cancer | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 19 | 2024-01-01 | 2023-12-12 |
| Cetuximab+Zimberelimab in Combination With Cisplatin and Nab-paclitaxel in Resctable Head and Neck Squamous Cell Carcinoma Cetuximab, Zimberelimab, Docetaxel - Hend and Neck Squamous Cell Carcinoma Locally Advanced Operable | Phase 2 | Unknown | Xuekui Liu | 52 | 2023-12-01 | 2023-11-22 |
| Adjuvant Chemoradiotherapy Followed by Zimberelimab for Locally Advanced Cervical Cancer. Zimberelimab, Platinum, radiotherapy - Cervical Cancer | Phase 2 | Not yet recruiting | Obstetrics & Gynecology Hospital of Fudan University | 24 | 2023-12-01 | 2023-11-30 |
| Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC Zimberelimab, Albumin-bound Paclitaxel, Cisplatin - Locally Advanced Cervical Cancer | Phase 2 | Recruiting | Tang-Du Hospital | 20 | 2023-10-09 | 2023-09-28 |
| SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study) Stereotactic body radiation(SBRT), Zimberelimab (GLS-010) - Locally Advanced Pancreatic Cancer | Phase 2 | Not yet recruiting | Peking University Third Hospital | 96 | 2023-08-01 | 2023-08-24 |
| Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer Quemliclustat, Etrumadenant, Zimberelimab - Oligometastatic Prostate Cancer | Phase 2 | Recruiting | Catherine Spina | 23 | 2023-07-01 | 2025-05-20 |
| A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma Zimberelimab 240mg - Classical Hodgkin Lymphoma | Phase 2 | Unknown | Sun Yat-sen University | 54 | 2023-06-14 | 2023-06-18 |
Showing 20 of 45. Sign in to see all of them.
Uterine Cervical Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (4) · Lung Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (3) · Triple Negative Breast Neoplasms (3) · Cholangiocarcinoma (2) · Neoplasm Metastasis (2) · Pancreatic Neoplasms (2) · Stomach Neoplasms (2) · Adenocarcinoma Of Esophagus (1) · Bile Duct Neoplasms (1) · Breast Neoplasms (1) · Carcinoid Tumor (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Neuroendocrine (1)
Arcus Biosciences, Inc. (5) · Gilead Sciences (5) · Guangzhou Gloria Biosciences Co., Ltd. (3) · Sun Yat-sen University (3) · Hospices Civils de Lyon (2) · Catherine Spina (1) · Coherus Oncology, Inc. (1) · Dana-Farber Cancer Institute (1) · Diwakar Davar (1) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) · Fudan University (1) · Fundación para el Progreso de la Oncología en Cantabria (1) · Gulam Manji (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · James Cleary, MD, PhD (1)
United States (25) · China (13) · France (8) · South Korea (7) · Italy (6) · Spain (6) · United Kingdom (6) · Taiwan (5) · Australia (4) · Canada (4) · Hong Kong (4) · Turkey (Türkiye) (3) · Germany (2) · Malaysia (2) · Poland (2)
Catherine S. Spina, MD, PhD (1) · Daniel Morgensztern, M.D. (1) · David Hsieh, MD (1) · Diwakar Davar, MD (1) · Encouse Golden, M.D., Ph.D. (1) · Giuseppe Procopio, MD (1) · Guiling Li, Doctor (1) · Gulam Manji, MD, PhD (1) · Hongxi Zhao, PhD (1) · Ignacio Duran, MD (1) · James Cleary, MD, PhD (1) · Jianmin Fang, Ph.D (1) · Jun Zhu, MD (1)
PMID 33929895, PMID 34462189, PMID 37875323, PMID 38261969, PMID 38682560, PMID 39186707, PMID 39799811, PMID 40592848, PMID 41109921, PMID 42481461
2023 (2), 2025 (1)